Yup. I agree. Who would have thought BG-12 stood a chance. But do you think the once-daily vs BID for BG-12 will make some MS patients less compliant in the real-world setting?
Also, ACOR -- - what / where can the company go from here. That's what I want to see. I keep waiting for them to in-lisence something good to add to their pipeline.
Market Data 
Markets 
AI
